Zhejiang CONBA Pharmaceutical Co Ltd Market Cap ($1.58 Billion)
Market Cap & Net Worth: Zhejiang CONBA Pharmaceutical Co Ltd (600572)
Zhejiang CONBA Pharmaceutical Co Ltd market cap. Zhejiang CONBA Pharmaceutical Co Ltd (SHG:600572) has a market capitalization of $1.58 Billion (CN¥10.81 Billion) as of November 8, 2026. Listed on the SHG stock exchange, this China-based company holds position #6774 globally and #1362 in its home market, demonstrating a 2.16% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Zhejiang CONBA Pharmaceutical Co Ltd's stock price CN¥4.26 by its total outstanding shares 2538532031 (2.54 Billion). Also see 600572 cash generation efficiency for how efficiently the company converts equity into cash flow.
Zhejiang CONBA Pharmaceutical Co Ltd Market Cap History (2015–2026)
Zhejiang CONBA Pharmaceutical Co Ltd market cap history from 2015 to 2026. Data shows change from $2.89 Billion to $1.58 Billion (-4.97% CAGR). Check latest Zhejiang CONBA Pharmaceutical Co Ltd stock price today for real-time trading data and today's change.
Zhejiang CONBA Pharmaceutical Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Zhejiang CONBA Pharmaceutical Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore 600572 shareholders equity momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.26x
Zhejiang CONBA Pharmaceutical Co Ltd's market cap is 0.26 times its annual revenue
Latest Price to Earnings (P/E) Ratio
3.49x
Zhejiang CONBA Pharmaceutical Co Ltd's market cap is 3.49 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $2.41 Billion | $6.02 Billion | $441.07 Million | 0.40x | 5.47x |
| 2017 | $2.38 Billion | $5.29 Billion | $711.12 Million | 0.45x | 3.34x |
| 2018 | $2.03 Billion | $7.02 Billion | $815.16 Million | 0.29x | 2.50x |
| 2019 | $2.16 Billion | $6.77 Billion | -$345.63 Million | 0.32x | N/A |
| 2020 | $1.65 Billion | $5.91 Billion | $453.30 Million | 0.28x | 3.65x |
| 2021 | $1.75 Billion | $6.57 Billion | $2.02 Billion | 0.27x | 0.87x |
| 2022 | $1.72 Billion | $6.00 Billion | $358.12 Million | 0.29x | 4.80x |
| 2023 | $1.88 Billion | $6.73 Billion | $591.57 Million | 0.28x | 3.17x |
| 2024 | $1.73 Billion | $6.52 Billion | $622.42 Million | 0.27x | 2.78x |
| 2025 | $1.66 Billion | $6.47 Billion | $474.36 Million | 0.26x | 3.49x |
Competitor Companies of 600572 by Market Capitalization
Companies near Zhejiang CONBA Pharmaceutical Co Ltd in the global market cap rankings as of November 8, 2026. Also see total assets of Zhejiang CONBA Pharmaceutical Co Ltd for a full breakdown of the balance sheet.
Key companies related to Zhejiang CONBA Pharmaceutical Co Ltd by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #511 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #530 globally with a market cap of $50.42 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #567 globally with a market cap of $47.07 Billion USD ( CN¥321.69 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #609 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #511 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #530 | GALDERMA GROUP AG | NYSE:GALDY | $50.42 Billion | $46.61 |
| #567 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $47.07 Billion | CN¥50.43 |
| #609 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €18.80 |
Market Capitalization of Zhejiang CONBA Pharmaceutical Co Ltd (2015–2026)
Market capitalization of Zhejiang CONBA Pharmaceutical Co Ltd from 2015 to today. Between 2015 and today, Zhejiang CONBA Pharmaceutical Co Ltd's market cap moved from $2.89 Billion to $ 1.58 Billion, with a yearly change of -4.97%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥1.58 Billion | -4.48% |
| 2025 | CN¥1.66 Billion | -4.29% |
| 2024 | CN¥1.73 Billion | -7.72% |
| 2023 | CN¥1.88 Billion | +9.12% |
| 2022 | CN¥1.72 Billion | -2.01% |
| 2021 | CN¥1.75 Billion | +6.16% |
| 2020 | CN¥1.65 Billion | -23.41% |
| 2019 | CN¥2.16 Billion | +6.07% |
| 2018 | CN¥2.03 Billion | -14.34% |
| 2017 | CN¥2.38 Billion | -1.56% |
| 2016 | CN¥2.41 Billion | -16.64% |
| 2015 | CN¥2.89 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 8th, 2026 the market cap of Zhejiang CONBA Pharmaceutical Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.58 Billion USD |
| MoneyControl | $1.58 Billion USD |
| MarketWatch | $1.58 Billion USD |
| marketcap.company | $1.58 Billion USD |
| Reuters | $1.58 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Zhejiang CONBA Pharmaceutical Co Ltd
Zhejiang CONBA Pharmaceutical Co.,Ltd. engages in the research, development, production, and sales of pharmaceuticals and health products in mainland China. It offers medicines, Chinese patent medicines, chemical medicines, Chinese herbal medicine slices, and health products. The company also provides Chinese decoction pieces; over-the-counter medications; healthy consumer products, including nut… Read more